How Real-World Evidence is Transforming Health Economics and Outcomes Research

Health Economics and Outcomes Research (HEOR) plays a pivotal role in shaping regulatory decisions, payer strategies, and commercial success. To make informed choices about treatment access, pricing, and reimbursement, stakeholders need comprehensive insights into patient safety, treatment efficacy, and long-term health outcomes.

This is where real-world evidence (RWE) becomes indispensable. By leveraging Qdata^®—Verana Health’s curated real-world data (RWD) from exclusive medical society partnerships—we help HEOR and Medical Affairs teams generate high-quality insights to support clinical and commercial decision-making.

The Power of Real-World Data in HEOR

When effectively curated, RWD enables HEOR teams to:

• Understand the patient journey: Track disease progression, treatment pathways, and patient adherence.
• Assess treatment outcomes: Compare therapies in real-world settings to evaluate their effectiveness and safety.
• Conduct postmarketing studies: Monitor long-term treatment effects to meet regulatory requirements and support market access.

By structuring and analyzing RWD through Qdata, we help translate raw data into actionable evidence that supports commercial, regulatory, and payer strategies.

Use Cases: Qdata Enhances HEOR and Medical Affairs Strategies

1. Understanding the Patient Journey: FDA-Funded Pediatric IOL Study

For HEOR teams, mapping the patient journey is crucial to evaluating treatment effectiveness and unmet needs. Using Ophthalmology Qdata, Verana Health conducted the largest FDA-funded study on pediatric intraocular lenses (IOLs) to date, analyzing real-world outcomes for a unique population of nearly 4,000 patients.

Key findings from the study include:

• Visual acuity improved at all post-surgical time points, with a mean of 20/70 after one year.
• Unilateral IOL implantation led to worse visual outcomes and a higher risk of complications.
• Posterior capsular opacification (PCO) was the most common adverse event.

This study underscores the value of retrospective RWD in informing clinical decision-making and supporting regulatory approvals. HEOR teams can leverage similar RWE approaches to track long-term safety and efficacy outcomes for innovative therapies.

2. Tracking Treatments and Outcomes: Ocular Therapeutix Postmarketing Study 

Long-term treatment safety and effectiveness are key concerns for regulators, payers, and life sciences companies. A postmarketing study of an Ocular Therapeutix treatment for cataract surgery utilized data from the American Academy of Ophthalmology IRIS^® Registry (Intelligent Research in Sight) to evaluate real-world utilization and patient outcomes following surgery.

Key insights from the study include:

• Analysis of 6 million cataract surgeries, making it one of the most extensive studies of its kind.
• Incidence of endophthalmitis (a rare, but serious eye infection) was assessed to fulfill an FDA postmarketing safety requirement.
• Real-world evidence replacing the need for a traditional postmarket clinical trial, reducing time and cost burdens while meeting regulatory requirements.

These findings provided critical evidence for regulatory reporting, payer negotiations, and commercial positioning, demonstrating how RWD can accelerate market access while ensuring ongoing patient safety.

3. Leveraging RWE for Regulatory and Payer Strategies

Regulators and payers require long-term evidence of a therapy’s safety and efficacy beyond clinical trials. With Qdata, we help HEOR teams generate postmarketing evidence that can shape formulary decisions, reimbursement negotiations, and market access strategies.

For example, Urology Qdata insights have been used to:

• Assess treatment persistence for benign prostatic hyperplasia (BPH) therapies.
• Compare real-world outcomes between minimally invasive and surgical interventions.
• Identify patient subgroups who may benefit from targeted therapeutic approaches.

Activating RWE for Smarter HEOR Decisions

At Verana Health, we believe that RWE should go beyond raw data—it should drive meaningful insights that accelerate innovation and improve patient outcomes. With Qdata, we enable HEOR and Medical Affairs teams to:

• Access high-quality, structured RWD from exclusive specialty society partnerships
• Conduct robust analyses on patient safety, treatment effectiveness, and healthcare utilization
• Support regulatory submissions, payer negotiations, and commercial planning with evidence-backed insights

By harnessing the power of curated RWD, we help life sciences companies optimize HEOR strategies, improve patient access, and shape the future of evidence-based care.

If your organization is looking to unlock the potential of real-world data for HEOR and Medical Affairs, let’s start a conversation. Together, we can transform healthcare through actionable evidence.